Health Risks and Benefits of Weight-Loss Drugs

The Health Risks and Benefits of Weight-Loss Drugs
Read More: Patients Are Suing Over Alleged Side Effects of Weight-Loss Drugs
What’s behind the meteoric rise of weight-loss drugs in Massachusetts?
About 140,400 obese patients in Massachusetts were prescribed medications like Wegovy and Zepbound in 2024, a 255 percent increase from 2023, according to a Globe analysis of insurance claims data.
Popular GLP-1 Drugs Are Shaping Health Beyond Weight Loss & Diabetes
In all, researchers found that people taking GLP-1 medications had lower risks for 42 health outcomes, including liver failure, lung failure, cardiac arrest, aspiration pneumonia and shock.
Weight-loss drugs linked to unexpected benefits and risks
The study revealed that weight-loss drugs significantly benefit neurological and behavioral health, including decreased risks of addiction.
Popular GLP-1 medications may have health benefits that extend beyond weight loss and blood sugar control, a new study finds
Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to reduce the risks of substance abuse disorders, psychosis, infections, some kinds of cancer and dementia,
Novo Nordisk says its obesity drug in higher dose shows 20.7% weight loss
Novo Nordisk said a higher dose of its drug Wegovy led to greater weight loss in patients during a late-stage trial, but the results fell short of the weight loss achieved with Eli Lilly's rival drug Zepbound,
Benefits and risks of popular weight-loss drugs revealed
Demand for weight-loss medications sold under brand names such as Ozempic and Wegovy continues to surge, with a recent study reporting one in eight Americans has taken or is currently using the drugs to treat diabetes,
Medicare to Negotiate Lower Prices for Weight-Loss Drugs
The government is expected to pay lower prices for Ozempic and Wegovy starting in 2027. The Trump administration will decide whether to expand coverage for millions of Americans.
E-sellers of compounded weight-loss drugs fail to reveal risks, research shows
By Bhanvi Satija and Christy Santhosh (Reuters) -Websites selling compounded versions of popular weight-loss drugs from Novo Nordisk and Eli Lilly to U.S. consumers often do not inform patients of the risks associated with these medicines,
Weight-loss drugs linked to benefits beyond dropping pounds
A new study published in the Nature Medicine monthly journal highlights the benefits and risks of weight-loss drugs like Ozempic and Wegovy. Positives include reduced risks of infections and cardiac arrest,
GLP-1 weight loss drugs linked to a wide range of health benefits and risks: study
A new peer-reviewed study based on data from nearly 2M individuals highlights a wide range of clinical benefits and risks, including several newly found conditions linked to the GLP-1 class of weight loss and diabetes drugs.
FDA Approves Weight-loss Drug Zepbound For Sleep Apnea – Will Insurance Cover This $1000-Per-Month Medication?
Zepbound is a dual-activating medication that combines glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like ...
Eli Lilly Stock Tumbles on Slower-Than-Expected Weight Loss Drug Sales. Is This a Buying Opportunity?
Eli Lilly unexpectedly lowered its full-year 2024 guidance. The miss appears to stem from a lack of the typical December ...
Are we nearing peak obesity as weight loss drugs gain popularity?
As weight loss medications like Ozempic and Wegovy become increasingly popular, questions arise about whether the nation is approaching pea ...